ABOS$0.2304-3.88%
Acumen Pharmaceuticals, Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$16.66M
Float & O/S:
Inst Own:
DilutionScan read 37 of Acumen Pharmaceuticals, Inc.'s SEC filings and found 1 warrant series, 1 convertible, 1 ATM program, 3 shelf registrations and 1 completed offering on file for ABOS. The latest dilution event on file is a registration statement on Oct 28, 2026. Analysis updated Oct 31, 2026.
Signal8 Summary
ABOS
Going-concern warning from auditors
Snapshot
Acumen is a clinical-stage biotech with no revenue and a serious cash problem. The company lost $121.3 million in FY 2025 while burning through $115.6 million in free cash flow.
What's Happening Right Now
- : Acumen presented data at AAIC 2026 showing its EBD candidate ACU401 achieved up to 40-fold greater frontal cortex exposure in non-human primates compared to native antibodies.
- : Acumen nominated two development candidates, ACU301 and ACU401, in its Enhanced Brain Delivery program under a license with JCR Pharmaceuticals.
- : The company reported a narrower Q1 net loss but raised substantial doubt about its ability to continue as a going concern, stating current cash may only fund operations into early 2027.
